Denosumab

Abstract

Denosumab, a fully human monoclonal antibody, binds to the receptor activator of nuclear factor-κB ligand (RANKL) and thereby inhibits RANKL-mediated bone resorption. In various individual countries, subcutaneous denosumab is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumours (featured indication… (More)
DOI: 10.2165/11207370-000000000-00000

3 Figures and Tables

Topics

  • Presentations referencing similar topics